Key result
High-dose intravenous recombinant interleukin-2 treatment caused reversible acute hypocholesterolemia, virtual disappearance of HDLs, and marked reduction in LDLs in metastatic cancer patients.
Why the study?
Does high-dose intravenous recombinant interleukin-2 alter lipoprotein profiles in patients with metastatic cancer?
Observational
Does high-dose intravenous recombinant interleukin-2 alter lipoprotein profiles in patients with metastatic cancer?
High-dose IL-2 therapy for metastatic cancer induces profound but reversible changes in lipid metabolism, including severe hypocholesterolemia and the appearance of remnant-like lipoproteins.
May warrant lipid monitoring during IL-2 therapy; case reports leave open metabolic and outcome implications.
Reversible acute hypocholesterolemia was observed during treatment of metastatic cancer with high-dose intravenous recombinant interleukin-2 (IL-2). Further analysis revealed virtual disappearance of high-density lipoproteins (HDLs) and marked reduction in the concentration of low-density lipoproteins (LDL); the remaining LDL and intermediate-density lipoproteins (IDL) were enriched in triglyceride relative to cholesterol and had broad-beta electrophoretic mobility, properties reminiscent of remnant lipoproteins. These changes differ qualitatively and quantitatively from those previously reported for other cytokines such as tumor necrosis factor (TNF) or the interferons (IFNs).
No takes yet. Share an insight, caveat, or question.
Wilson et al. (1989) conducted an observational in Metastatic cancer. Recombinant interleukin-2 (IL-2) was evaluated on Lipoprotein profile changes (hypocholesterolemia, HDL, LDL, IDL). High-dose intravenous recombinant interleukin-2 treatment caused reversible acute hypocholesterolemia, virtual disappearance of HDLs, and marked reduction in LDLs in metastatic cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: